stereotactic injection of nondiffusible dyes
TO THE EDITOR: We read with interest the paper by Margetis et al. 3 (Margetis K, Rajappa P, Tsiouris AJ, et al: Intraoperative stereotactic injection of Indigo Carmine dye to mark ill-defined tumor margins: a prospective Phase I-II study. J Neurosurg 122: 40-48, January 2015) . Our group in Treviso used a very similar technique and published the results about 25 years ago. 1, 2 We similarly used nonspreading dyes to highlight the tumor borders before performing the craniotomy and consequently before brain shift could occur. Methylene blue was injected to label the tumor boundaries. The only differences were the use of a stereotactic frame, because the frameless navigation system was not available at that time, and the injection of the dye through a single bur hole. With this technique, the mass is encompassed in a cone, with its apex at the entry point and its base at the deepest face of the tumor. The colored tracks can be also helpful to reach the tumor, minimizing the damage to the normal brain tissue. Our series included 25 patients harboring not only WHO I-IV gliomas (19 cases), but also cavernomas and metastasis.
Of course, nowadays we would not recommend such a method to resect cavernomas, which are much better localized using neuronavigation. However, we agree with Margetis et al. when they say that stereotactic injection of nondiffusible dyes can be useful to better visualize tumor margins for improving the extent of removal, reducing damage to normal brain tissue, and avoiding inaccuracies due to brain shift. Moreover, this technique has very limited costs, which is of great interest for the large number of neurosurgical departments that cannot afford the expenses related to more updated and technologically advanced techniques to localize and intraoperatively outline brain tumors.
After the publication of our first 25 patients in 1990, we have been using dye injection until recent years in selected cases. The injection of nondiffusible dyes should be considered as a possible tool especially for deep-seated tumors and for low-grade gliomas, whose limits are often difficult to guess intraoperatively. Coupling this technique with cortical and subcortical neurophysiological mapping is likely to maximize the resection and better preserve functionally eloquent areas. We thank Drs. Feletti and Longatti for bringing to our attention their work on the stereotactic injection of methylene blue for delineating the border of brain tumors prior to surgery. 3,4 Their work predates our paper and clearly represents the first stereotactic injection of dye in the brain for these purposes. As such, they should be credited for proof of concept. The differences in the techniques (e.g., framed vs frameless stereotaxy, single vs multiple bur holes for dye injection, the use of preoperative CT vs MRI, and the use of brain cannula vs spinal needle) are not based on different fundamental concepts, but rather they represent technological advances that occurred between the two studies.
Alberto Feletti, MD, PhD
However, we wish to point out another key difference, which is that our study required approval from the FDA for an investigational new drug study emphasizing the safety of the pharmaceutical compound used. The use of methylene blue by the Treviso group hinders the generalizability of their method. Several reports 1,2,5,6 -with the first one being published 66 years ago 7 -have established the toxicity of methylene blue after intrathecal injection. In the light of these reports it would be problematic to use methylene blue for this technique. The use of methylene blue was eliminated from consideration very early in the planning phase of our study, which may explain why the Treviso study eluded our literature review. Ultimately, we are pleased to reiterate and confirm the utility of stereotactic injection of dyes for tumor delineation as a helpful adjunct in neuro-oncological surgery even in the age of intraoperative MRI scans.
Konstantinos Margetis, MD, PhD
Theodore H. schwartz, MD 121:1219 121: -1231 121: , November 2014 , which addressed the potential of noninvasive stimulation for treating posttraumatic cognitive impairment, but also pointed out the possible risk of functional impairment depends on the stimulation site and parameters.
One of the most prevalent neuropsychiatric outcomes of traumatic brain injury (TBI), particularly severe TBI, is personality change. 5,6 These changes, as reported by Tate et al. (1999) , can more precisely be defined as behavioral manifestations of cognitive deficits acquired after the TBI. 8 Most likely, this intimate relationship between cognitive deficits and personality changes explains the latter as a highly independent factor that is associated with not returning to work in survivors of severe TBI. 4 Noninvasive cerebral stimulation is a promising intervention for the treatment of cognitive impairment after TBI. 1 According to Villamar et al., 9 the acute recovery of cerebral functions after brain injury includes the activation of cellular repairs, which occurs in the earlier weeks following injury, cellular plasticity, and anatomical plasticity, including the formation of new connections. After the acute phase, remyelization and plasticity are the main processes that occur-particularly during the 3 months following the trauma. Certain methods of cerebral stimulation are able to suppress some of the pathological events and to reinforce other favorable processes, inducing cognitive and motor function recovery, which in turn help to minimize incapacitating sequelae. 9 Accordingly, the theoretical use of adequate noninvasive cerebral stimulation early after TBI could result in a neuroprotective action that may help to reduce the incidence and severity of longterm neuropsychiatric complications of TBI. Nevertheless, the risks of transcranial magnetic stimulation (TMS)-induced seizures and skull conductance modifications, for example, especially in severe TBI victims, could limit the use of such interventions in the period immediately after the trauma; indeed, the potential for neuropsychological damage may even be intensified with their application. 1 Still, the identification of biomarkers with sufficient accuracy to discriminate among those individuals with a higher chance of a worse prognosis could help to evaluate a risk/benefit relationship linked to early interventions, such as noninvasive cerebral stimulation.
In a recent study, we demonstrated that the duration of posttraumatic amnesia (PTA) was independently associated with personality changes, a clinical entity that is deeply connected with global cognitive deficits. 3 An important limitation of that study, the retrospective evaluation of PTA, could be eliminated with prospective data collection, permitting the identification of the cutoff for the risk of personality changes as well as predicting specific cognitive deficits that are associated with both behavioral disorders and impaired activities of daily living, including the ability to return to work. These issues are being investigated by an ongoing multicenter study.
Noninvasive cerebral stimulation for enhancing cognition in neuropsychiatric disorders is undoubtedly a promising method. 2 Compared to other brain diseases, such as Alzheimer's disease, schizophrenia, autism spectrum disorders, and attention deficit hyperactivity disorder, TBI has the benefit of the exact time of onset of the pathophysiological process being known. This advantage facilitates the completion of studies using noninvasive techniques as a neuroprotective method for individuals with higher risks of cognitive sequelae.
The possibility of mitigating the cognitive deficits associated with TBI using noninvasive brain stimulation in an early phase after trauma based on the duration of PTA in higher-risk individuals could have a positive impact on reducing the social burden associated with TBI. In particular, this treatment strategy could minimize the personal and familial suffering that accompanies severe TBI for a significant portion of survivors.
